Christopher DiSimone

Statistics

Publications

Citations

1.3K

H-Index

Active since

2019

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Arizona Oncology

University of Pennsylvania

Fred Hutch Cancer Center

University of Washington

Christopher DiSimone is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer pharmacology, medicine, and pembrolizumab therapy.

Publications per year

2019–2021

Publications

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker, Matthew H. Taylor, Carol Aghajanian et al. · Journal of Clinical Oncology · 2020 · 522 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason et al. · Journal of Clinical Oncology · 2021 · 126 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer.

Marcia S. Brose, Nicholas J. Vogelzang, Christopher DiSimone et al. · Journal of Clinical Oncology · 2019 · 14 citations

Medicine, Oncology, Pharmacotherapy +16

1–4 of 4